Strides Pharma Science jumps 4 per cent on receiving USFDA approval

Strides Pharma Science jumps 4 per cent on receiving USFDA approval

Abhinav Lahoti
/ Categories: Trending, DSIJ News

Strides Pharma Science Ltd informed on Friday during the market hours that its step-down wholly-owned subsidiary, Strides Pharma Global Pte Limited, Singapore, has received approval for Prednisone tablets USP, 10 mg & 20 mg from USFDA.  

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Deltasone tablets, 10 mg and 20 mg, of Pharmacia and Upjohn Co. (Pharmacia).  

The US market for these kinds of tablets is approximately US$ 60 million as per IQVIA MAT December 2020 data. The company currently has 127 cumulative ANDA filings with USFDA, out of which, 98 ANDAs have been approved while the remaining 29 are still pending approval.   

On Friday, the shares of the company reacted positively after the news and closed at a price of Rs 885.00, which is 2.16 per above its previous closing price.   

Previous Article Buzzing small-cap: Prima Plastics hits new 52-week high
Next Article Alembic Pharmaceuticals rises over 3 per cent on receiving USFDA nod for Treprostinil injection
Rate this article:
4.5

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR